Clinical Trials Logo

Adult Congenital Heart Disease clinical trials

View clinical trials related to Adult Congenital Heart Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT06260059 Not yet recruiting - Heart Failure Clinical Trials

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

EmpaCHD
Start date: February 2024
Phase: Phase 4
Study type: Interventional

The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).

NCT ID: NCT05270356 Enrolling by invitation - Clinical trials for Adult Congenital Heart Disease

MINDS Imaging Ancillary Study

MINDS
Start date: May 27, 2021
Phase:
Study type: Observational

This study is an ancillary study to the NHLBI-funded Pediatric Heart Network (PHN) "Multi-Institutional Neurocognitive Discovery Study" (MINDS) in Adult Congenital Heart Disease (ACHD). The MINDS-ACHD" study will recruit 500 complex CHD patients between18-30 years old. The investigators propose to quantitate multi-modal neuroimaging biomarkers (brain injury, structure and physiology) which are not only important components of brain and cognitive reserve but can be predictive of neurocognitive decline and early onset of dementia in the aging non-CHD population.

NCT ID: NCT04787705 Active, not recruiting - Cardiac Surgery Clinical Trials

Multicenter Validation of a Predictor Model of ACHD Patients and Cardiac Surgery

Start date: March 10, 2020
Phase:
Study type: Observational

This multicentre study is to validate prediction modeling for the ACHD population undergoing cardiac surgery. The validation of this prediction model will support and generalize its use as a risk stratification tool in the ACHD population.

NCT ID: NCT04136379 Completed - Clinical trials for Congenital Heart Disease

Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD

Start date: September 30, 2019
Phase:
Study type: Observational

Summary: Congenital heart disease (CHD) is the most prevalent form of birth defect with a global rate of 1.35 million newborns born with CHD annually. Patients with CHD have an increased risk of cerebrovascular accident (CVA) compared to age-matched control populations. Anticoagulation with warfarin is the mainstay of antithrombotic treatment in these patients and requires frequent monitoring of the International Normalized Ratio (INR). The CoaguChek monitor is a point of care device that enables patients to self-monitor and manage their INR without the need to attend a warfarin clinic. The aim of this study is to compare the efficacy and outcomes of standard clinic management and home management of INR in patients with CHD. Analysis of time in therapeutic range (TTR), INR variability, major and minor bleeding events, incidence of CVA and other thrombotic events will be undertaken. Original Hypothesis: There will be a difference in the proportion of time that patients spend in their therapeutic range and the amount of adverse events that occur between those who use a CoaguChek monitor and those who use standard clinic monitoring of their INR. The primary outcome will be time in therapeutic range (TTR). Secondary outcomes will be INR variability, minor / major bleeding complications and thromboembolic events.